VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Prevnar
Vaccine Information
  • Vaccine Name: Prevnar
  • Target Pathogen: Streptococcus pneumoniae
  • Target Disease: Pneumonia
  • Product Name: Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)
  • Tradename: Prevnar
  • Manufacturer: Wyeth Pharmaceuticals Inc.
  • Vaccine Ontology ID: VO_0000090
  • CDC CVX code: 100
  • Type: Conjugate vaccine
  • Status: Licensed
  • Location Licensed: USA (License #0003)
  • Host Species for Licensed Use: Human
  • Antigen: A sterile solution of saccharides of the capsular antigens of Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F individually conjugated to diphtheria CRM197 protein (FDA: Prevnar).
  • Preparation: Each serotype is grown in soy peptone broth. The individual polysaccharides are purified through centrifugation, precipitation, ultrafiltration, and column chromatography.
  • Storage: DO NOT FREEZE. Store refrigerated at 2°C TO 8°C.
  • Approved Age for Licensed Use: 2-15 months of age.
  • Contraindication: Hypersensitivity to any component of the vaccine, including diphtheria toxoid, is a contraindication to use of this vaccine.
  • Description: In the USA, a heptavalent pneumococcal conjugate vaccine vaccine (PCV 7) (e.g. Prevnar) is recommended since 2000 for all children aged 2–23 months and for at-risk children aged 24–59 months. The normally 4-doses series is given at 2, 4, 6 & 12–14 months of age. Protection is good against deep pneumococcal infections (especially septicemia and meningitis) (Wiki: S. pneumoniae).
Host Response

Human Response

  • Vaccination Protocol: Efficacy was assessed in a randomized, double-blinded clinical trial in a multiethnic population at Northern California Kaiser Permanente (NCKP) from October 1995 through August 20, 1998, in which 37,816 infants were randomized to receive either Prevnar or a control vaccine at 2, 4, 6, and 12-15 months of age (FDA: Prevnar).
  • Immune Response: There were no reports of streptococcus pneumoniae in the group vaccinated with PREVNAR whereas in the control group, there were between 17-22 cases reported after vaccination (FDA: Prevnar).
  • Side Effects: Side effects of vaccination include: fever, irratibility, drowsiness, decreased appetite, rash and soreness/redness of the injection site.
References
FDA: Prevnar: FDA: Pneumococcal 7-valent Conjugate Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094057.htm]
Wiki: S. pneumoniae: Wikipedia: Streptococcus pneumoniae [http://en.wikipedia.org/wiki/Streptococcus_pneumoniae]